Chief Operating Officer
CurrentYmmunobio AG is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. As COO, I am leveraging my substantial industry, consulting, and business development experience to advance Ymmunobio's strategy for novel and first-in-class antibody research.